We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Healthcare Inv | LSE:HIO | London | Ordinary Share | GB00B94T6Y14 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 14.75 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCOS
Collagen Solutions PLC
18 September 2017
Collagen Solutions Plc
(the "Company" or the "Group")
Presenting at the Hardman Investor Forum
Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that Jamal Rushdy, CEO of the Company, will be presenting at an investor evening hosted by Hardman & Co on Wednesday 20 September at DWF LLP, 20 Fenchurch Street, London EC3M.
The event provides an opportunity for investors to hear about the progress being made by the Company and the potential for its own products going forward. David Evans, Chairman, and Gill Black, CFO, will also be in attendance to network and answer questions from the audience after the formal proceedings have been completed. Registration is from 5.30pm for a prompt start at 6.00pm.
To register for the event please and obtain further details, please contact Hardman & Co on gl@hardmanandco.com
Jamal Rushdy, CEO of Collagen Solutions said: "The Hardman Forum gives us a good opportunity to update shareholders and other investors on the progress of our commercial strategy as well as the development programmes for the key products which we anticipate will play a very significant part in the growth of the Company over the next few years."
About Collagen Solutions:
Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic. The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.
No new material information will be disclosed. Presentation slides, will be available from 18:00hrs on September 20 on the Collagen Solutions website at:
http://ir.collagensolutions.com/content/investors/presentations.asp
Enquiries:
Collagen Solutions Plc Contact via Walbrook Jamal Rushdy, Chief Executive Officer Gill Black, Chief Financial Officer Walbrook PR Tel: 020 7933 8780 or collagen@walbrookpr.com Mike Wort Mob: 07900 608 002 Anna Dunphy Mob: 07876 741 001
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAGIGDCBXBBGRL
(END) Dow Jones Newswires
September 18, 2017 02:01 ET (06:01 GMT)
1 Year Healthcare Inv Chart |
1 Month Healthcare Inv Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions